Keyphrases
Neuroblastoma
100%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
71%
Urokinase-type Plasminogen Activator
71%
Urokinase Plasminogen Activator System
57%
Refractory Neuroblastoma
28%
Targeted Agents
28%
Monoclonal Antibody
28%
Tumor Cells
28%
Tumor Progression
28%
Novel Targeted Agents
14%
Validation Studies
14%
In Vitro Activity
14%
Tumor Cell Proliferation
14%
Tumor Subtype
14%
Unique Attributes
14%
Melanoma
14%
Inhibiting Activity
14%
Glioma Cancer
14%
Adult Cancer
14%
Tumor Metastasis
14%
Neuroblastoma Cell Line
14%
Myeloma
14%
New Drugs
14%
Target Validation
14%
Clinical Samples
14%
Therapeutic Strategies
14%
Ovarian Cancer
14%
Drug Delivery
14%
Pediatric Population
14%
Poor Prognosis
14%
Chemotherapy Drugs
14%
Tumorgraft
14%
Pediatric Neuroblastoma
14%
Chemotherapy
14%
New Drug Targets
14%
Clinical Trials
14%
Cell Death
14%
Prostate Cancer
14%
Acute Myeloid Leukemia
14%
Colon Cancer
14%
Therapeutic Target
14%
Lung Cancer
14%
Pancreatic Cancer
14%
Antitumor Activity
14%
Breast Cancer
14%
Cancer Treatment
14%
Patient-derived
14%
Medicine and Dentistry
Ganglioneuroblastoma
100%
Urokinase
90%
Tumor Cell
30%
In Vitro
20%
Tumor Progression
20%
Monoclonal Antibody
20%
Clinical Trial
10%
Ovarian Cancer
10%
Acute Myeloid Leukemia
10%
Patient Population
10%
Ganglioglioma
10%
Myeloma
10%
Pancreas Cancer
10%
Pediatrics Patient
10%
Antineoplastic Activity
10%
Cell Proliferation
10%
Metastatic Carcinoma
10%
Breast Cancer
10%
Lung Cancer
10%
Neoplasm
10%
Prostate Cancer
10%
Receptor
10%
Neuroblastoma Cell Line
10%
Cancer Treatment
10%
Malignant Neoplasm
10%
Pediatrics
10%
Biological Product
10%
Cell Death
10%
Chemotherapy
10%
Colon Cancer
5%
Nodular Melanoma
5%
Colon Carcinoma
5%
Melanoma
5%